EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

IMPROVING MALARIA PREVENTION IN IMMUNOCOMPROMISED GROUPS: A PUBLIC HEALTH IMPERATIVE IN AFRICA

Emmanuel Ifeanyi Obeagu, Kenedy Kyaluzi

Universal Journal of Pharmaceutical Research · 15.03.2026

DOI: 10.22270/ujpr.v11i1.1495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Universal Journal of Pharmaceutical Research, online erschienen am 15.03.2026. Verfasst von Emmanuel Ifeanyi Obeagu und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a major public health challenge in Africa, disproportionately affecting vulnerable populations, especially immunocompromised groups such as individuals living with HIV/AIDS, malnourished children, and patients undergoing immunosuppressive therapies. These populations are at increased risk of malaria infection, experience more severe disease manifestations, and face poorer treatment outcomes due to compromised immune function. Despite significant advances in malaria control, existing prevention strategies often do not adequately address the unique needs of immunocompromised individuals. This review explores the pathophysiological interplay between malaria and immunosuppression, highlighting how immune deficits exacerbate susceptibility and severity of malaria infections. Current malaria prevention measures—including vector control, chemoprophylaxis, and health education—are assessed with a focus on their applicability and limitations in immunocompromised populations. Key barriers such as health system fragmentation, socio-economic constraints, and emerging insecticide and drug resistance are identified as critical challenges that undermine prevention efforts. To reduce the disproportionate malaria burden in immunocompromised groups, the review advocates for integrated healthcare services, targeted vector control, expanded prophylactic interventions, and enhanced community engagement. Strengthening research and surveillance will inform tailored, evidence-based policies. Ultimately, a comprehensive and collaborative public health approach is essential to safeguard the health of Africa’s most vulnerable populations and accelerate progress toward malaria elimination. Peer Review History: Received 1 December 2025; Reviewed 12 January 2026; Accepted 17 February; Available online 15 March 2026 Academic Editor: Prof. Cyprian Ogbonna ONYEJI, Obafemi Awolowo University, Ile-Ife, Nigeria, conyeji@oauife.edu.ng Reviewers: Noha El Baghdady, MTI University, Cairo, Egypt, nohasalah21@yahoo.com Prof. Gorkem Dulger, Duzce University, Turkey, gorkemdulger@yandex.com

Zitieren

APA

Obeagu, E. I., & Kyaluzi, K. (2026). IMPROVING MALARIA PREVENTION IN IMMUNOCOMPROMISED GROUPS: A PUBLIC HEALTH IMPERATIVE IN AFRICA. Universal Journal of Pharmaceutical Research. https://doi.org/10.22270/ujpr.v11i1.1495

Vancouver

Obeagu EI, Kyaluzi K. IMPROVING MALARIA PREVENTION IN IMMUNOCOMPROMISED GROUPS: A PUBLIC HEALTH IMPERATIVE IN AFRICA. Universal Journal of Pharmaceutical Research. 2026. doi:10.22270/ujpr.v11i1.1495

BibTeX
@article{Obeagu2026,
  author = {Obeagu, Emmanuel Ifeanyi and Kyaluzi, Kenedy},
  title = {IMPROVING MALARIA PREVENTION IN IMMUNOCOMPROMISED GROUPS: A PUBLIC HEALTH IMPERATIVE IN AFRICA},
  journal = {Universal Journal of Pharmaceutical Research},
  year = {2026},
  doi = {10.22270/ujpr.v11i1.1495}
}
Kostenlos starten →